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Abstract
Objective Bladder cancer (BC) has the highest lifetime
treatment costs per patient of all cancers. The high recur-
rence rate and ongoing invasive monitoring requirement are
the key contributors to the economic and human toll of this
disease. The purpose of this paper was to utilize the recent
literature to identify opportunities for improving the bene-
Wts and costs of BC care.
Methods A PubMed search was performed of recent pub-
lications concerning (BC) cost-eVectiveness. We reviewed
studies, reviews, opinion papers and cost-eVectiveness
analyses, focusing primarily on non-muscle-invasive blad-
der cancer (Ta/T1; NMIBC).
Results New diagnostic tools such as urine markers may
assist in more cost-eVectively detecting BC at an earlier
stage, however, these markers cannot replace the cystos-
copy, which is the current standard of care. A photody-
namic diagnostic tool (PDD) using hexylaminolevulinate
(Hexvix®) enhances tumor visibility and improves transure-
thral resection of bladder cancer (TURB) results, poten-
tially reducing recurrence rates and lowering treatment
costs. While the importance of BC research has been
acknowledged, research investment has been continuously
reduced during the last 5 years.
Conclusions The economic burden of BC is well-charac-
terized in the literature. This study suggests that new tech-
nologies (i.e., urine-based tests, PDD) and therapeutic
regimes (intravesical chemotherapy, adjuvant immunother-
apy) have signiWcant potential to improve the diagnosis,
treatment and on-going monitoring of BC patients, with
potential improvements in clinical outcomes and concur-
rent cost-savings. A renewed interest and investment in BC
research are required to ensure future advancements.
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Background and objective
Bladder cancer (BC) has the highest lifetime treatment
costs per patient (pp) of all cancers, followed by colorectal,
breast, prostate, and lung cancer [1]; costs have increased
steadily since 1996 [2]. Worldwide, 336,000 patients were
diagnosed with BC in 2000 [2]. The American Cancer
Society estimated 50,040 incident cases for 2007 [3], and
treatment costs for non-muscle invasive bladder cancer
(NMIBC) in the United States (US) are estimated at
$157.5 M over 5 years [4]. Although most patients present
with NMIBC (70% (78% females; 64% males)), the high
rate of recurrence and disease progression necessitates
vigilant long-term monitoring for BC patients.
The enormous human, psychological and economic bur-
den of BC underscores the importance of optimizing diag-
nosis and treatment protocols. However, relevant data are
sparse, making it diYcult to adequately assess cost beneWt
for current standards of BC care. The purpose of this paper
was to use the available BC data to identify potential oppor-
tunities for improving the overall cost beneWt proWle of BC
care.
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Methods
A PubMed search was performed on literature published
between 2003 and 2008 using MeSH terms: cost-eVective-
ness, screening, tumor markers, photodynamic diagnostic
(PDD), transurethral resection of the bladder (TURB) and
BC. The search included prospective and retrospective
studies, reviews, opinion papers, and cost eVective analyses
as well as European Association of Urology (EAU) and
American Urology Association (AUA) guidelines for
NMIBC and muscle invasive BC (MIBC).
Results
Economic burden of bladder cancer
Depending on the country, BC costs from diagnosis-to-death
range between $89,287 and $202,203 pp [5] and will likely
increase as survival rates increase. In the US, 2006 total can-
cer costs were estimated at $206.3B with estimated productiv-
ity losses of $17.9B for cancer-related morbidity and $110.2B
for cancer-related mortality [3]. On average, 12 years of
income-producing life are lost with each premature death [6].
Among cancers in the US, BC has the highest pp treatment
costs, and the 5th highest overall cost [5], estimated at $3.4B
annually with $2.9B in direct treatment-related costs, and
indirect costs of $184,762 to $461,907 pp [7].
The United Kingdom (UK) reported a 2001–2002 total
NMIBC and MIBC costs of £55.39 M ($82,395 M) or
£8,349 pp ($12,409), of which 60% was spent managing
NMIBC [8]. This cost diVerential likely stems from the
higher incidence, recurrence, and survival rates of NMIBC
[8]. NMIBC has an average 60–80% recurrence rate, of
which 40–60% recurs within 2 years, with 10–30% of the
patients progressing to MIBC which requires more invasive
and costly treatment [9]. Monitoring, which is essential given
the high BC recurrence rates, generates signiWcant on-going
costs. About 75% of the post-diagnosis costs relate to
pre-operative and intra-operative management including
post-surgical complications, tri-annual examinations and
semi-annual diagnostic and laboratory testing [10].
Several strategies for reducing BC’s economic burden
have been proposed: (1) use of urine-based markers to
identify incident or recurrent tumors earlier [8]; (2) use of
outpatient facilities for TURB reducing hospitalizations if
surgical risks can be minimized [8]; (3) improve eYcacy of
intravesical treatments. Finally, but not yet proven, is the
use of photodynamic diagnosis (PDD), instead of conven-
tional white-light cystoscopy, to improve initial TURB
eYcacy and potentially reduce NIMBC’s residual risk [11].
Potential role for non-invasive diagnostic tools
With an estimated 4% incidence in a healthy population,
BC screening results in a 3.0 life-year gain per 1,000
patients, a 50% reduction in disease progression and a cost
savings of $101,000 pp [12]. Although urine-based mark-
ers, like NMP-22, seem to be cost-eVective for the high-risk
population, they will not reduce cystoscopy requirements
and must be tested in prospective trials to determine their
value in the general population. The estimated cost per
diagnosis (i.e., direct cost divided by observed sensitivity)
for NMP-22 is ($39.82), cytology ($54.96), cystoscopy
($430.14), and CT urogram ($989.06). Cystoscopy was
more sensitive than the other modalities in diagnosing BC
(P < 0.05), although the combination of cystoscopy with
other tests yielded no statistically signiWcant improvements
in sensitivity [13].
Potential to improve clinical outcomes and cost of care
After hematuria, positive cytology or positive urine-based
markers, a diagnostic cystoscopy is performed, followed by
TURB if needed. The average annualized rate of TURB in
US Medicare patients with a BC diagnosis is 51% and is
generally consistent across genders, geographic regions,
and racial and ethnic groups. The annualized TURB rate
varies by age, ranging from 46% among 65–69-year-olds to
60% among 90–94 year old beneWciaries [14].
TURB represents, by far, the largest BC expenditure,
accounting for 71% of treatment costs in the UK [8].
Table 1 shows TURB costs in Europe, ranging from D845
($1,124) (France) to D2,231 ($2,967) (Germany) [15].
Costs are similar in Japan (¥281,600 ($2,428)) but higher in
the US $5,305 (D3,453) [16].
The quality and result of the initial TURB strongly deter-
mines the patient’s prognosis and overall BC treatment costs.
Table 1 Average European BC treatment reimbursement (procedure and hospital stay inclusive)
The bolded amounts highlight the lowest and highest reimbursement
$ The exchange rate was calculated on the basis of 1Euro = 1.33 US$ and 1£ = 1.47US$
UK in £ ($) Germany in D ($) France in D ($) Italy in D ($) Belgium in D ($)
Cystoscopy 422 (620) 46 (61) 38 (51) 57 (76) 40 (53)
TURB 1,465 (2,154) 2,231 (2,967) 845 (1,124) 2,061 (2,741) 1,655 (2,201)
Cystectomy 3,867 (5,684) 15,419 (20,507) 9,697 (12,897) 7,222 (9,605) 10,932 (14,540)World J Urol (2009) 27:295–300 297
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Photodynamic diagnosis
Photodynamic diagnosis (PDD) is an emerging technology
with signiWcant potential for improving the eVectiveness of
TURB. PDD was introduced using 5-aminolevulinic acid
(5-ALA). Since 2005, hexylaminolevulinate (HAL or
HEXVIX®) has been approved in 27 European countries
and recommended in EAU NIMBC Guidelines [17–20].
Hexylaminolevulinate induces protoporphyrin IX (PpIX)
production in the bladder where the increased PpIX build-
up better illustrates precancerous and cancerous lesions.
When performing a PDD blue light cystoscopy, PpIX Xuo-
rescence is produced by excitation with blue light resulting
in a red-to-purple Xuorescence.
PDD supports a more complete resection [11] and has
been reported as improving oncological patient outcome,
reducing recurrence rates by approximately 20 and pro-
longing recurrence-free survival [21]. The learning curve
for PDD TURB resulting in a more complete tumor resec-
tion can be shortended by utilizing the virtual TURB train-
ing system (Karl Storz® Tuttlingen, Germany) [22].
The experience of the author’s department (Table 2)
illustrates Daniltchenko et al.’s hypothesis that the initial
PDD costs can be oVset by fewer TURB follow-ups [18]. In
a separate prospective series of 115 patients (void of adju-
vant treatment), recurrence rates after 60 months were 59%
after PDD and 75% following white-light cystoscopy. The
researchers in that study estimated that, in using PDD, they
have avoided at least 20 additional TURBs over a 5-year
follow-up, clearly demonstrating that the beneWts associ-
ated with PDD outweigh the costs [23].
The statistically signiWcant advantage of decreased BC
recurrence after PDD has been reported to persist for at
least 8 years [21]. Hedelin et al. concluded that if PDD
were used in high-risk patients (15% of all newly diagnosed
BC patients estimated at 1720 new cases of BC per year in
Sweden alone), it could save D500 K ($665 K) in the Wrst
year alone. If PDD were used for all TURBs in high and
medium risk patients, the Wrst year savings would be
D405,000 ($536,650) and D363,000 ($482,790), respec-
tively [24]. A recent German study also revealed that PDD
signiWcantly reduced costs related to recurring NMIBC
[19].
Intravesical chemotherapy and adjuvant immunotherapy
Depending on tumor stage, the EAU guidelines recommend
intravesical chemotherapy or adjuvant immunotherapy fol-
lowing TURB. Two primary drugs are currently used:
alkylating agents like mitomycin (MMC) and diVerent
strains of Bacillus Calmette-Guerin (BCG) [17].
MMC is generally considered the Wrst-line agent for
low-risk tumors and can be administered immediately after
TURB, however, this practice is considered “unlabelled” in
the US and some other countries [5]. In patients with inter-
mediate and high-risk BC tumors, a single administered
shot of intravesical chemotherapy should be followed by
additional instillations or BCG [17]. MMC after TURB has
reduced recurrence by as much as 50% compared with
transurethral resection alone [25].
Tolley et al. [26] reported a statistically signiWcant
decrease in the tumor recurrence in NMIBC patients treated
Table 2 TURB cost calculation: comparison of conventional TURB versus PDD assisted TURB based on a diagnose related group in a German
Hospital
DRG Diagnosis related group
a Hardware equipment cost calculated for an individual TURB and PDD based on an estimated 300 TURBs/year over 10 years
b TURB cost (includes average time of surgeon, anethesiologist, nurse/technician, equipment cost)
c Pathologist cost for four random biopsies
d The chance of a re-TURB in relation to the published results of D’Hallewin et al. [40] and Daniltchenko et al. [18]
Source University of Tuebingen, Department of Urology
$ The exchange rate was calculated on the basis 1Euro = 1.33 US$
Cost parameter Conventional TURB in D ($) PDD assisted TURB in D ($) DiVerence in (§) D ($)
Preop.catheter 0,00 (0,00) 23,00 (30,59) +23,00 (+30,59)
Hexvix® 0,00 (0,00) 412,50 (548,62) +412,50 (+548,62)
Equipment/10 yearsa 7,10 (9,44) 10,70 (14,23) +3,60 (+4,78)
Bladder TURBb 900,00 (1197,00) 900,00 (1197,00) 0,00 (0,00)
Histology tumor 40,63 (54,03) 40,63 (54,03) 0,00 (0,00)
Histo 4 corner Bxc 121,38 (161,44) 0,00 (0,00) ¡121,38 (¡161,44)
20% chance of 2nd TURB 
after 3/6 mos. (DRG)d
458,00 (609,14) 0,00 (0,00) ¡458,00 (¡609,14)
Total/TURB 1527,11 (2031,06) 1386,83 (1844,48) ¡140,28 (¡168,57)298 World J Urol (2009) 27:295–300
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with MMC within a 24-h period following TURB com-
pared to those who did not receive instillation. If the instil-
lation was performed the following day, the relative risk of
tumor recurrence was estimated to be doubled [27]. Bohle
et al. [28] conducted a meta-analysis comparing 1328
NMIBC patients treated with adjuvant-MMC versus 1421
patients treated with BCG. Without a clear separation
between intermediate and high-risk patients, the overall
recurrence rate was 46.4% for MMC and 38.6% for BCG
after a 26-month mean follow-up. MMC demonstrated
fewer side eVects. Comparable beneWcial eVects have been
demonstrated for MMC, epirubicin, and doxorubicin [25].
BCG is generally reserved for high-risk tumors and Wrst-
line treatment for carcinoma in situ [29]. If the risk of an
adverse reaction prevents the use of BCG for carcinoma in
situ, intravesical MMC may be given instead [30]. Uchida
et al. [16] reported the mean total BCG treatment cost was
¥224,566 ($1,936)pp. Their 5-year recurrence-free patient
survival rate with and without BCG instillation therapy was
78 and 28%, respectively. Accordingly, the cost-eVective-
ness ratio was ¥449,132 ($3,872) over 5-year recurrence-
free period (60,906 ¥/year;$525/year) [16].
Kilbridge et al. [31] found that an average 65-year-old
male with high-grade superWcial disease treated with BCG
gains 6 months life expectancy at an incremental cost of
$1,660, or $3,320 per year of life saved. The incremental cost
eVectiveness of BCG was still better than many other
accepted medical practices. Both BCG and MMC are consid-
ered superior to other intravesical agents (such as interferon-
or anthracycline antibiotic-related chemotherapy) for reducing
recurrences; however, it is unclear if any intravesical therapy
ultimately aVects the rate of progression to MIBC [32].
Bottemann et al. [5] estimated the cost-beneWt ratio in
100 new NMIBC patients treated with adjuvant intravesical
chemotherapy; 20 would be tumor-free at 3 months and
would no longer require further TURBs resulting in savings
of £30,000 ($44,100). It could be expected that a lower
recurrence risk would lead to a less intensive cystoscopic
follow-up regime, resulting in further potential savings in
the Wrst year post-initial TURB of approximately £13,500
($19,845) (HRG estimate of cystoscopy cost £450 ($662)
resulting in 30 less cystoscopies annually). This example
suggests a net savings of £45,500 ($66,882) per 100 new
NMIBC patients.
The combination of PDD TURB and MMC intravesical
instillation might help to reduce the BC recurrence that
would help to reduce the cost over the long term.
Cost consequences of disease progression
The MIBC patient treatment costs are nearly three times
those for patients with stage Tis/Ta and two times for those
patients with TNM stage T1. On average, the bladder-
related complications contributed $249, $384, and $775 to
the monthly patient costs with stage Tis/Ta, T1, and MIBC,
respectively. Systemic-related complications (SRCs) added
monthly costs averaging $500 in 21% of the patients with
NMIBC and $700 in 40% of MIBC patients. The mean,
annual post-diagnosis continuing care costs pp were esti-
mated at $4,975, $7,100 and $17,437 for those with Tis/Ta,
T1 and MIBC [33]. The US Medicare annual cost for
continuing care for the 3634 NMIBC patients and 2083
with MIBC totaled $21 million and nearly $36 million,
respectively. During the preceding 4 months, BC-related
care added an estimated $4.7 million to each total [33].
Konety et al. reported median total charges of $53,342
for patients with radical cystectomies. Medical complica-
tions, which occurred in approximately 28% of patients
increased costs at least $15,000 [34]. The total annual
incremental medicare expenditures for MIBC patients, with
and without adjustment for co-morbidity, were more than
twice those of NMIBC patients (2006 US $99.3 M versus
$41.8 M, respectively) [33].
Avritscher et al. [35] estimated the BC lifetime mean
treatment cost at $99,270 for MIBC patients and $120,684
for NMIBC patients, with an annual average of 36 hospital-
ization days for MIBC patients vs. 1.3 days per year for
NMIBC patients. Admissions and surgical procedures
accounted for 50% of the total costs ($32,559) and surveil-
lance for and treatment of tumor recurrences, accounted for
60% ($39,393). In addition, 30% of the total cost ($19,811)
was attributable to treatment of complications: 26%
($16,934) for MIBC and 4% ($2,312) for NMIBC.
Progression from NMIBC to MIBC clearly increases
overall treatment costs. Early detection of incident and
recurrent disease plays a key role in reducing the risk of
disease progression, as do emerging technologies, such as
PDD, and adjuvant therapies, such as MCC and BCG.
Economic impact of cancer on patients and families
There is another side of the enormous Wnancial burden that
cancer exerts on patients and their families. Low-income
patients undergoing cancer treatment spent approximately
27% of their annual income on out-of-pocket medical
expenses [36]. Twenty-seven percent had to delay or forego
treatment and 6% Wled for bankruptcy [37]. A study by
YabroV et al. [38] showed that the estimated patient’s cost
for time spent traveling, waiting for appointments and
receiving services or procedures during the Wrst 12 months
after diagnosis was as much as $5605.
Bladder cancer research investment
Sangar et al. [8] commented that research funding allocation
in the UK for BC is not commensurate with its WnancialWorld J Urol (2009) 27:295–300 299
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burden. They estimate that BC and prostate cancer incur
similar annual healthcare costs pp yet research funding var-
ied markedly, with £4.62 M ($6.808 M) for BC and
£20.56 M ($30.295 M) for prostate cancer. In the US, the
NCI’s investment [39] in BC research decreased from
$35.5 M in Wscal year 2003 to $19.8 M in Wscal year 2007
for one of the highest ranked cancers; conversely, total can-
cer research investment increased $4.6 to $4.8B [39].
Conclusion
Current state-of-the-art NMIBC and MIBC treatments
incorporate recently developed diagnostic and therapeutic
tools like urine-based markers or HAL-photo dynamic diag-
nostics that further increase the initial BC treatment cost.
More cost-eVective treatments are essential in BC therapy,
especially in this current Wnancially-strained time. This
topic paper concludes that, while these new treatment
options initially provoke higher costs after the initial diagno-
sis, long-term cost beneWts can be achieved through reduced
tumor recurrence and potentially reduced progression rates.
In addition to PDD use, the training of urologic surgeons
must be improved as the chosen initial surgical therapy has a
profound impact on the patient and total BC costs. Special
attention should be considered in future studies with the com-
bined use of HAL-PDD, intravesical MMC chemotherapy and
other treatment possibilities where diagnostic and treatment
tools will not only be evaluated with the clinical sensitivity
and speciWcity in mind, but also judged by their long-term
cost eVectiveness. A renewed interest and investment in BC
research are essential to ensure future advancements.
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